Related Experiment Videos
Verbascoside triggers apoptosis and ferroptosis in NSCLC by targeting BCAT2
Ruijuan Li1, Bin Li1, Ping Wang1
1Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Background:
The treatment of non-small cell lung cancer (NSCLC) has challenges such as drug resistance and recurrence. Concurrently, the induction of apoptosis and ferroptosis is a promising therapeutic strategy. This study aimed to investigate whether the natural product, verbascoside, induces apoptosis and ferroptosis in NSCLC cells by targeting BCAT2.
Methods:
Bioinformatic analysis was used to predict the potential targets of verbascosides. Stable cell lines with BCAT2 knockdown and overexpression were constructed. The effects of verbascoside on NSCLC were evaluated in vitro and using a mouse xenograft model.
Results:
Bioinformatics screening and molecular docking identified BCAT2 as a potential target of verbascoside, with a significantly stronger binding energy (-7.8 kcal/mol) than another candidate, PARP1. In vitro and in vivo experiments confirmed that BCAT2 knockdown significantly inhibited NSCLC cell viability, induced apoptosis and ferroptosis, and induced mitochondrial damage. Conversely, BCAT2 overexpression produced opposite effects. Verbascoside treatment inhibited BCAT2 expression in a concentration-dependent manner, recapitulating the apoptotic, ferroptotic, and mitochondrial damage phenotypes induced by BCAT2 knockdown; however, BCAT2 overexpression significantly reversed these effects of verbascoside. In an animal model, treatment with verbascoside significantly suppressed tumor growth and activated apoptosis and ferroptosis in tumor tissues by downregulating BCAT2.
Conclusions:
Verbascoside can induce apoptosis and ferroptosis in NSCLC by directly targeting and inhibiting BCAT2, leading to mitochondrial dysfunction. This finding not only reveals BCAT2 as a novel target of verbascoside but also confirms its ability to induce apoptosis and ferroptosis in NSCLC cells.
Insights
Verbascoside induces apoptosis and ferroptosis in non-small cell lung cancer (NSCLC) by targeting BCAT2. This natural compound offers a promising strategy against NSCLC drug resistance and recurrence.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) presents treatment challenges including drug resistance and recurrence.
- Inducing apoptosis and ferroptosis is a key therapeutic strategy for NSCLC.
- Verbascoside, a natural product, is explored for its potential in NSCLC treatment.
Purpose of the Study:
- To investigate if verbascoside induces apoptosis and ferroptosis in NSCLC cells.
- To determine if BCAT2 is a molecular target of verbascoside in NSCLC.
- To evaluate the therapeutic potential of verbascoside in NSCLC models.
Main Methods:
- Bioinformatic analysis and molecular docking to identify verbascoside targets.
- Construction of NSCLC cell lines with altered BCAT2 expression (knockdown and overexpression).
- In vitro assays and a mouse xenograft model to assess verbascoside efficacy.
Main Results:
- BCAT2 identified as a high-affinity target of verbascoside.
- BCAT2 knockdown inhibited NSCLC viability and induced apoptosis, ferroptosis, and mitochondrial damage.
- Verbascoside suppressed tumor growth and activated apoptosis/ferroptosis by downregulating BCAT2 in vivo.
Conclusions:
- Verbascoside induces apoptosis and ferroptosis in NSCLC by directly targeting and inhibiting BCAT2.
- BCAT2 is a novel therapeutic target for verbascoside in NSCLC treatment.
- Verbascoside demonstrates potential as an anti-NSCLC agent via BCAT2-mediated mitochondrial dysfunction.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
Cellular Injury V: Apoptosis and Autophagy
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
The Extrinsic Apoptotic Pathway
Apoptosis